Vor Bio (VOR) on Thursday announced an amendment to its existing agreement with RemeGen (REGMF) to add the Chinese biotech’s next-gen dual BAFF/APRIL inhibitor RC298 in a deal worth up to $356M.
Under the agreement, the Boston, Massachusetts-based biotech will receive an